Trial reportAnaesthesiology intensive therapy2025
Influence of magnesium sulfate on the pharmacodynamic characteristics of rocuronium. A randomized clinical trial.
Trial report in Anaesthesiology intensive therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Magnesium sulfate pharmacology for maternal and critical-care indications: mechanisms, pharmacokinetics, and the therapeutic window.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a multimodal anesthesia adjuvant, magnesium sulfate (MgSO4) plays an important role in the anesthetic arsenal, due to its properties and substantial synergistic effects with other drugs such as opioids, hypnotics and neuromuscular blocking drugs (NMBD). Rocuronium is a non-depolarizing NMBD used widely in general anesthesia, and its association with MgSO4 is still a concern. This study aimed to evaluate the influence of MgSO4 at a dose of 30 mg kg-1 on the pharmacodynamic characteristics of rocuronium.
methodsIt was a double-blinded, randomized controlled trial in adult female patients scheduled for open hysterectomies with total intravenous anesthesia. Patients were allocated randomly to receive MgSO4 (30 mg kg-1) diluted in 100 mL of saline, 10 minutes before induction, or 100 mL of saline. Primary outcome: Influence of MgSO4 on latency (onset time), clinical duration (CD25%) and time to recover 90% of T4/T1 - train of four (TOF = 0.9). In total, 70 patients were enrolled, 35 per group.
resultsThe baseline characteristics were similar. A comparative analysis showed a significant difference between the groups regarding latency in seconds (lower with MgSO4) 40.00 (35-45 [30-68]) compared to saline 53.00 (50-60 [40-90]) (P < 0.001), CD25% in minutes (longer with MgSO4) 61.00 (53-70 [30-110]), saline 38.00 (35-48 [30-87 (P <0.001), and TOF = 0.9 in minutes, longer with MgSO4 98.00 (88-111 [53-176]), saline 60.00 (55-78 [44-130]) (P < 0.001). MgSO4 was found to reduce opioid consumption in the postanesthetic care unit.
conclusionsThe strong impact of MgSO4 on the pharmacodynamics of rocuronium confirms the indispensable role of quantitative neuromuscular blockade monitoring to guide reversal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.